These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Loss of heterogeneous ribonucleoprotein A(2)/B(1) expression in thyroid neoplasms.
    Author: Bidot P, Morgan M, Zhukov T, Tannenbaum M, Tockman MS.
    Journal: Endocr Pract; 2001; 7(3):157-61. PubMed ID: 11421561.
    Abstract:
    OBJECTIVE: To determine whether a difference exists in the immunohistochemical expression of heterogeneous ribonucleoprotein (hnRNP) A(2)/B(1) between benign and malignant thyroid lesions and to assess whether a gradient of expression could be found in normal thyroid, adenomas, and thyroid malignant tumors. METHODS: Formalin-fixed, paraffin-embedded archival tissues from 32 cases (8 nodular goiters, 8 follicular adenomas, 8 follicular carcinomas, and 8 papillary carcinomas) were immunostained with monoclonal antibody 703D4, directed against hnRNP A(2)/B(1), applied at a concentration of 10 microg/mL. The streptavidin-biotin peroxidase method was used to label bound monoclonal antibody. Positivity was independently scored by two pathologists, who used a three-tiered scale. RESULTS: The benign thyroid tissues, including the hyperplastic and adenomatous lesions, demonstrated 3+ granular cytoplasmic staining for hnRNP A(2)/B(1), except in two cases (one nodular goiter and one follicular adenoma) in which 2+ staining intensity was noted. In contrast, the papillary and follicular carcinomas failed to stain with the antibody, except in two cases that showed weak (1+) staining. CONCLUSION: hnRNP A(2)/B(1) immunostaining appears to distinguish benign from malignant thyroid lesions. Loss of hnRNP A(2)/B(1) expression seems to be a characteristic feature of thyroid malignant lesions.
    [Abstract] [Full Text] [Related] [New Search]